BIO Deutschland: Partner of SME Focus – Personalised Medicine
|Michael Kahnert (BIO Deutschland), Norbert Gerbsch
(BPI) and Martin Walger (VDGH) opened the event,
photo: Florian Dahnke/BIOCOM AG
The focus was on small and medium-sized enterprises (SMEs) during the one-day Personalised Medicine event, which was organised by BIOCOM and took place in Berlin on 7 March. BIO Deutschland was a cooperation partner of the event and was thus able to offer its members a discount on admission. The event’s wide-ranging programme explored the various aspects of IT and diagnostics in personalised medicine for biotechnology and pharmaceutical SMEs. Most of the speakers came from BIO Deutschland member companies. The agenda included presentations and lively discussion on problems with filing patent applications, for example in the light of the Myriad ruling; the future of companion diagnostics; the need to integrate data that are relevant to patients and diseases; and many other topics. During his presentation, Dirk Biskup, managing director of CeGaT, explained the potential of panel tests and the benefits of conducting the entire analysis of samples in-house in order to have better control of data protection. “May we – or must we – use retrospective findings without first conducting prospective studies?” was the question posed for discussion by Anna Eichhorn, CEO of Humatrix. Overall, the cooperation partners agreed that in addition to the important task of continuing to improve conditions for innovative SMEs, there should be a greater focus on patients and on patient information.
Further information and photographs are available at www.transkript.de/bilder-videos/events/personalisierte-medizin-fokus-mittelstand.html